PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

NCT07410520 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma (PCNSL)
Secondary Central Nervous System Lymphoma (SCNSL)

Interventions

DRUG: PD -1/PD-L1 monoclonal antibody
DRUG: Rituximab (R)
DRUG: Methotrexate
DRUG: Orelabrutinib
PROCEDURE: ASCT/WBRT

Sponsor

The First Affiliated Hospital with Nanjing Medical University